ebola
viru
ebov
signific
human
pathogen
present
public
health
concern
emergingreemerg
viru
potenti
biolog
weapon
substanti
progress
made
last
decad
develop
candid
prevent
vaccin
protect
nonhuman
primat
ebov
among
prospect
vaccin
base
recombin
vesicular
stomat
viru
vsv
particularli
robust
also
confer
protect
administ
postexposur
treatment
concern
rais
regard
replicationcompet
vsv
vector
express
ebov
glycoprotein
vector
would
toler
individu
alter
compromis
immun
system
patient
infect
hiv
especi
import
ebov
outbreak
date
occur
area
central
western
africa
high
hiv
incid
rate
popul
order
address
concern
evalu
safeti
recombin
vsv
vector
express
zair
ebolaviru
glycoprotein
vsvdgzebovgp
six
rhesu
macaqu
infect
simianhuman
immunodefici
viru
shiv
six
anim
show
evid
ill
associ
vsvdg
zebovgp
vaccin
suggest
vaccin
may
safe
immunocompromis
popul
one
goal
studi
evalu
safeti
candid
vaccin
platform
also
interest
determin
alter
immun
statu
would
affect
vaccin
efficaci
vaccin
protect
shivinfect
macaqu
death
follow
zebov
challeng
evalu
cell
anim
show
anim
succumb
lethal
zebov
challeng
lowest
count
suggest
cell
may
play
role
mediat
protect
zebov
ebola
viru
ebov
associ
sporad
episod
hemorrhag
fever
hf
produc
sever
diseas
infect
patient
mortal
rate
outbreak
rang
sudan
ebolaviru
sebov
zair
ebolaviru
zebov
review
recent
outbreak
caus
appar
new
speci
ebov
uganda
appear
less
pathogen
sebov
zebov
preliminari
case
fatal
rate
ebov
also
consid
potenti
biolog
weapon
categor
categori
bioterror
agent
center
diseas
control
prevent
vaccin
postexposur
treatment
modal
avail
prevent
manag
ebov
infect
least
four
differ
vaccin
system
shown
promis
complet
protect
nonhuman
primat
lethal
ebov
challeng
prospect
ebov
vaccin
two
system
one
base
replicationdefect
adenoviru
base
replicationcompet
vesicular
stomat
viru
vsv
shown
provid
complet
protect
administ
singl
inject
vaccin
intriguingli
vsvbase
vaccin
vaccin
shown
util
administ
postexposur
treatment
two
lead
ebov
vaccin
candid
confer
protect
singl
inject
vaccin
advantag
disadvantag
adenoviru
vector
highli
immunogen
document
clinic
trial
evalu
gene
transfer
efficaci
immun
respons
replicationdefect
adenoviru
vector
also
perceiv
safer
human
use
replicationcompet
vaccin
signific
challeng
adenovirusbas
vaccin
concern
signific
portion
global
popul
preexist
antibodi
adenoviru
vector
may
affect
efficaci
perform
poorli
vaccin
vector
recent
clinic
trial
contrast
preexist
immun
vsv
human
popul
neglig
efficaci
like
greater
replicationcompet
vector
main
concern
vsv
vaccin
vector
replicationcompet
vector
may
present
signific
safeti
challeng
human
particularli
alter
immun
statu
ebov
outbreak
man
occur
exclus
central
western
africa
popul
region
among
may
benefit
develop
avail
ebov
vaccin
howev
popul
region
among
medic
disadvantag
world
particular
preval
individu
compromis
immun
system
high
hiv
infect
rate
rang
area
vsv
vaccin
vector
enorm
success
protect
healthi
immunocompet
anim
ebov
uncertain
vector
would
behav
individu
alter
compromis
immun
system
therefor
conduct
studi
assess
pathogen
protect
efficaci
recombin
vsvbase
zebov
vaccin
vector
rhesu
macaqu
infect
simianhuman
immunodefici
viru
shiv
known
deplet
popul
naiv
cell
naiv
cell
memori
cell
anim
order
take
account
degre
sever
compromis
immun
function
anim
select
vari
degre
cell
loss
recombin
vsv
express
glycoprotein
gp
zebov
strain
mayinga
vsvdgzebovgp
gener
describ
recent
use
infecti
clone
vsv
indiana
serotyp
zebov
strain
kikwit
isol
patient
zebov
outbreak
kikwit
nine
filovirusseroneg
adult
rhesu
macaqu
macaca
mulatta
kg
use
studi
macaqu
infect
three
month
prior
current
studi
kindli
provid
dr
ranajit
pal
advanc
bioscienc
laboratori
inc
kensington
md
anim
clinic
laboratori
evid
shiv
infect
evidenc
reduc
cell
count
decreas
ratio
cell
tabl
presenc
shiv
plasma
four
nine
anim
tabl
six
nine
shivinfect
anim
vaccin
im
inject
recombin
vsvdgzebovgp
three
anim
serv
placebo
control
inject
parallel
salin
six
vsvdg
zebovgpvaccin
anim
two
three
control
ebola
viru
among
lethal
microb
known
man
case
fatal
rate
often
exceed
sinc
discoveri
outbreak
sporad
geograph
restrict
primarili
area
central
africa
howev
concern
natur
unnatur
introduct
ebola
outsid
endem
area
dramat
increas
research
interest
public
awar
number
candid
vaccin
develop
combat
ebola
viru
vaccin
shown
vari
degre
success
nonhuman
primat
model
safeti
signific
concern
vaccin
particular
vaccin
replic
host
evalu
safeti
replicationcompet
vesicular
stomatitu
viru
vsv
base
ebola
vaccin
shivinfect
rhesu
monkey
found
vaccin
caus
evid
overt
ill
immunocompromis
anim
also
demonstr
vaccin
partial
protect
shivinfect
monkey
lethal
ebola
challeng
appear
associ
level
lymphocyt
surviv
studi
suggest
vsvbase
ebola
vaccin
safe
immunocompromis
popul
support
studi
develop
promis
vaccin
platform
use
human
anim
challeng
day
singl
dose
immun
pfu
zebov
strain
kikwit
monkey
challeng
heterolog
kikwit
strain
zebov
macaqu
model
develop
character
use
strain
anim
close
monitor
evid
clinic
ill
eg
temperatur
weight
loss
chang
complet
blood
count
blood
chemistri
vaccin
zebov
challeng
portion
studi
addit
vsvdgzebov
zebov
viremia
shed
analyz
vaccin
challeng
respect
anim
given
physic
exam
blood
swab
nasal
oral
rectal
collect
day
vaccin
day
zebov
challeng
vaccin
portion
studi
conduct
bioqual
approv
niaid
bioqual
usamriid
laboratori
anim
care
use
committe
zebov
challeng
perform
biocontain
usamriid
approv
usamriid
laboratori
anim
use
committe
anim
research
conduct
complianc
anim
welfar
act
feder
statu
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
facil
use
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
total
white
blood
cell
count
white
blood
cell
differenti
red
blood
cell
count
platelet
count
hematocrit
valu
total
hemoglobin
mean
cell
volum
mean
corpuscular
volum
mean
corpuscular
hemoglobin
concentr
determin
blood
sampl
collect
tube
contain
edta
use
laserbas
hematolog
analyz
coulter
electron
hialeah
fl
usa
white
blood
cell
differenti
perform
manual
wrightstain
blood
smear
serum
sampl
test
concentr
albumin
alb
amylas
ami
alanin
aminotransferas
alt
aspart
aminotransferas
ast
alkalin
phosphatas
alp
gammaglutamyltransferas
ggt
glucos
glu
cholesterol
chol
total
protein
tp
total
bilirubin
tbil
blood
urea
nitrogen
bun
creatinin
cre
use
piccolo
pointofcar
blood
analyz
abaxi
sunnyval
ca
usa
flow
cytometri
circul
cell
popul
ul
whole
blood
ad
tube
incub
antibodi
minut
room
temperatur
sampl
lyse
fix
paraformaldehyd
wash
three
time
pb
sampl
analyz
becton
dickinson
fac
calibur
becton
dickinson
san
jose
ca
antibodi
purchas
becton
dickinson
clone
use
measur
plasma
siv
rna
level
quantit
taqman
rna
revers
transcriptionpcr
rtpcr
assay
appli
biosystem
foster
citi
ca
use
target
conserv
region
siv
gag
accur
detect
limit
low
rna
copiesml
briefli
isol
plasma
viral
rna
use
gener
cdna
use
onestep
rtpcr
master
mix
appli
biosystem
sampl
amplifi
previous
describ
follow
pcr
primerprob
sivf
agtatgggcagcaaatgaat
forward
primer
sivr
tcttctgcgtg
aatgc
revers
primer
sivp
gatamra
taqman
probe
sequenc
detect
system
cycl
second
minut
signal
compar
standard
curv
known
concentr
determin
viral
copi
present
sampl
assay
lower
limit
copiesml
rna
isol
blood
swab
use
tripur
reagent
invitrogen
grand
island
new
york
detect
vsv
use
qrtpcr
assay
target
matrix
gene
nt
posit
zebov
rna
detect
use
qrtpcr
assay
target
l
gene
nt
posit
low
detect
limit
zebov
assay
pfuml
plasma
viru
titrat
perform
plaqu
assay
vero
cell
blood
select
organ
liver
spleen
lung
kidney
adren
gland
pancrea
axillari
lymph
node
inguin
lymph
node
mesenter
lymph
node
ovari
testi
brain
swab
sampl
briefli
increas
dilut
sampl
adsorb
vero
monolay
duplic
well
ml
per
well
thu
limit
detect
pfuml
igg
antibodi
zebov
detect
enzymelink
immunosorb
assay
elisa
use
purifi
viru
particl
antigen
sourc
previous
describ
necropsi
perform
anim
select
tissu
collect
histolog
analysi
histolog
immunohistochemistri
perform
previous
describ
zebovinfect
monkey
employ
nine
shivinfect
rhesu
macaqu
six
anim
vaccin
im
inject
singl
dose
vsvdgzebovgp
subject
remain
three
anim
control
receiv
steril
salin
anim
monitor
close
clinic
symptom
shed
recombin
vsv
none
anim
vaccin
vsvdgzebovgp
treat
salin
show
overt
fever
evid
clinic
ill
day
vaccin
period
importantli
evid
reaction
vaccin
inject
site
note
among
vsvdgzebovgpvaccin
anim
chang
note
activ
behavior
vaccin
phase
studi
day
day
vaccin
addit
chang
detect
hematolog
clinic
chemistri
follow
vaccin
mild
vsvdgzebovgp
viremia
pfuml
detect
day
vaccin
viru
isol
figur
rtpcr
data
shown
four
six
vsvdgzebovgpimmun
macaqu
subject
surprisingli
two
anim
lowest
count
subject
never
show
detect
level
vsv
viremia
vsvdgzebovgp
undetect
analyz
swab
sampl
data
shown
thu
vaccin
led
transient
viremia
viru
replic
yet
undetermin
site
viru
shed
vaccin
viru
follow
success
complet
safeti
portion
studi
six
vsvdgzebovgpvaccin
shivinfect
monkey
two
three
placebo
control
shivinfect
monkey
challeng
day
singl
immun
im
inject
pfu
zebov
strain
kikwit
four
six
vsvdgzebovgpvaccin
shivinfect
monkey
placebo
control
anim
start
show
clinic
sign
diseas
day
challeng
includ
fever
subject
control
lymphopenia
thrombocytopenia
subject
control
tabl
diseas
progress
two
vsvdgzebovgpvaccin
shivinfect
monkey
subject
placebo
control
anim
develop
addit
evid
clinic
ill
includ
increas
level
serum
enzym
associ
liver
function
depress
anorexia
appear
macular
rash
tabl
four
anim
succumb
zebov
challeng
two
vsvdg
zebovgpvaccin
monkey
expir
day
subject
subject
placebo
control
succumb
day
control
control
zebov
challeng
figur
diseas
progress
two
vsvdgzebovgpvaccin
shivinfect
monkey
febril
subject
chang
hematolog
valu
day
subject
anim
remain
healthi
surviv
zebov
challeng
figur
remain
vsvdgzebovgpvaccin
macaqu
subject
never
show
evid
clinic
ill
surviv
figur
interestingli
vsvdgzebovgpvaccin
macaqu
succumb
two
anim
signific
reduct
cell
tabl
lowest
total
cell
count
tabl
highest
shiv
viremia
tabl
evid
vsv
viremia
figur
suggest
cell
may
play
role
protect
blood
sampl
analyz
challeng
evid
zebov
replic
plaqu
assay
rtpcr
day
placebo
control
anim
develop
high
zebov
titer
plasma
detect
plaqu
assay
log
pfuml
tabl
comparison
one
vsvdgzebovgpvaccin
monkey
subject
show
zebov
viremia
day
plaqu
assay
log
pfuml
tabl
zebov
detect
second
vsvdgzebovgpvaccin
monkey
subject
day
log
pfuml
rtpcr
sensit
show
evid
zebov
plasma
anim
subject
day
addit
rtpcr
sensit
detect
zebov
swab
posit
number
sampl
deriv
subject
day
day
tabl
contrast
zebov
detect
plasma
viru
isol
rtpcr
four
vsvdgzebovgpvaccin
monkey
surviv
zebov
challeng
moreov
evid
reactiv
vsvdg
zebovgp
detect
blood
swab
sampl
anim
zebov
challeng
data
shown
although
fail
detect
zebov
viremia
two
surviv
anim
clinic
ill
subject
day
zebov
challeng
exclud
possibl
anim
low
level
circul
zebov
time
point
evalu
four
surviv
vsvdgzebovgpvaccin
macaqu
subject
euthan
day
zebov
challeng
perform
virolog
patholog
examin
tissu
organ
infect
titrat
four
anim
show
evid
zebov
tissu
examin
comparison
zebov
recov
tissu
vsvdgzebovgpvaccin
anim
succumb
subject
shivinfect
control
anim
organ
titer
infecti
zebov
consist
valu
previous
report
immunocompet
zebovinfect
rhesu
macaqu
vsvdgzebovgp
recov
tissu
examin
anim
studi
patholog
immunohistochem
evalu
tissu
four
vsvdgzebovgpvaccin
anim
subject
surviv
zebov
challeng
show
evid
zebov
antigen
contrast
zebov
antigen
readili
detect
typic
target
organ
eg
liver
spleen
adren
gland
lymph
node
two
vsvdgzebovgpvaccin
anim
succumb
zebov
challeng
subject
figur
two
placebo
control
lesion
distribut
zebov
antigen
macaqu
consist
result
report
studi
cellular
immun
respons
zebov
gp
macaqu
vaccin
vsvdgzebovgp
vector
difficult
detect
challeng
previou
studi
humor
immun
respons
robust
consist
tw
geisbert
unpublish
observ
therefor
measur
antibodi
respons
rhesu
macaqu
vaccin
vsvdgzebovgp
vaccin
day
vaccin
day
day
zebov
challeng
day
day
vaccin
igg
elisa
none
six
vsvdgzebovgpvaccin
macaqu
develop
igg
antibodi
titer
zebov
gp
day
zebov
challeng
figur
two
anim
subject
develop
modest
igg
antibodi
titer
zebov
day
zebov
challeng
day
vaccin
third
anim
develop
titer
day
zebov
challeng
day
vaccin
figur
often
rais
concern
regard
use
recombin
vsv
vaccin
platform
human
relat
fact
replicationcompet
vaccin
thu
demonstr
safeti
paramount
import
take
account
previou
work
surpris
vsvdgzebovgp
toler
well
shivinfect
macaqu
specif
fail
observ
evid
advers
event
larg
cohort
macaqu
receiv
vsv
vector
express
differ
gp
viral
hf
agent
cynomolgu
macaqu
rhesu
macaqu
vaccin
vsvdgzebovgp
cynomolgu
macaqu
tabl
clinic
find
shivinfect
rhesu
monkey
challeng
zebov
day
day
day
subject
fever
lymphopenia
thrombocytopenia
thrombocytopenia
anorexia
depress
moder
rash
epistaxi
thrombocytopenia
alpqqq
altqqq
astqqq
bunqqq
creqqq
ggtqqq
gluq
day
control
fever
anorexia
depress
lymphopenia
thrombocytopenia
alpqq
astq
anorexia
depress
moder
rash
day
fever
defin
temperatur
uf
baselin
least
uf
baselin
uf
mild
rash
focal
area
petechia
cover
less
skin
moder
rash
area
petechia
cover
skin
sever
rash
area
petechia
andor
echymosi
cover
skin
transient
vsv
viremia
studi
observ
surviv
macaqu
anim
succumb
zebov
challeng
figur
viremia
data
previou
studi
support
correl
vsv
viremia
surviv
addit
evid
vaccin
vector
shed
detect
studi
support
previou
result
compel
evid
suggest
occasion
viru
shed
detect
rtpcr
neg
viru
isol
would
lead
vaccin
vector
transmiss
vsv
glycoprotein
exchang
vector
employ
studi
also
shown
promis
prevent
vaccin
postexposur
treatment
marburg
hf
prevent
vaccin
lassa
fever
nonhuman
primat
similar
recombin
vsv
vector
evalu
anim
model
vaccin
candid
number
virus
caus
diseas
human
includ
influenza
viru
respiratori
syncyti
viru
measl
viru
herp
simplex
viru
type
hepat
c
viru
sever
acut
respiratori
syndrom
coronaviru
mani
studi
employ
vsv
vector
maintain
either
entir
vsv
glycoprotein
g
transmembran
andor
cytoplam
domain
protein
facilit
effici
incorpor
foreign
antigen
known
vsv
g
import
vsv
protein
associ
pathogen
shown
truncat
cytoplasm
tail
greatli
reduc
vector
pathogen
mice
follow
intranas
inocul
indic
import
domain
pathogen
regard
vsv
vector
includ
portion
vsv
g
express
hiv
gene
found
insuffici
attenu
clinic
evalu
assess
neurovirul
nonhuman
primat
investig
subsequ
show
safeti
immunogen
improv
genet
manipul
vsv
genom
remain
unclear
whether
neurovirul
associ
vsv
g
genom
manipul
nevertheless
zebov
vaccin
gdefici
vsv
vector
thu
lack
gassoci
pathogen
well
target
vsvspecif
neutral
antibodi
asid
g
vsv
matrix
protein
associ
cytopath
effect
vitro
includ
inhibit
host
gene
express
induct
cell
round
induct
apoptosi
larg
unclear
extent
alon
contribut
pathogen
inocul
studi
vsvbase
vaccin
differ
anim
speci
describ
suggest
major
pathogen
effect
protein
vivo
current
mechan
filoviru
vaccin
confer
protect
nonhuman
primat
well
understood
nearli
studi
detect
modest
good
humor
immun
respons
vsvdgzebovgp
vaccin
humor
respons
detect
macaqu
day
vaccin
tw
geisbert
unpublish
observ
howev
current
studi
consist
impair
immun
system
shivinfect
macaqu
develop
humor
immun
respons
time
zebov
challeng
three
anim
develop
modest
antizebov
igg
titer
day
zebov
challeng
uncertain
four
six
vsvdgzebovgpvaccin
macaqu
surviv
zebov
challeng
regardless
humor
immun
respons
elicit
anim
unlik
antibodi
alon
confer
protect
specif
passiv
antibodi
studi
nonhuman
primat
use
varieti
antizebov
immun
reagent
includ
polyclon
equin
immun
globulin
recombin
human
monoclon
antibodi
convalesc
monkey
blood
uniformli
fail
provid
protect
importantli
fail
provid
benefici
effect
number
studi
evalu
cellular
immun
respons
nonhuman
primat
vaccin
ebov
result
mix
studi
show
modest
cellular
respons
studi
show
weak
andor
cellular
immun
respons
howev
like
intracellular
cytokin
assay
employ
studi
sensit
thorough
enough
detect
cellular
immun
respons
zebov
inde
report
inabl
demonstr
robust
cellular
respons
may
illustr
limit
evalu
cellular
immun
respons
use
small
number
function
measur
interferongamma
one
interest
find
current
studi
may
begin
shed
light
mechan
protect
elicit
vsvdgzebovgp
notabl
two
rhesu
macaqu
group
togeth
sever
loss
cell
anim
fail
surviv
zebov
challeng
suggest
cell
may
play
role
mediat
protect
immun
ebov
infect
cell
shown
deplet
nonhuman
primat
follow
zebov
infect
vitro
zebov
infect
human
peripher
blood
mononuclear
cell
caus
massiv
bystand
death
cell
apoptosi
rodent
appear
faith
reproduc
zebov
infect
human
nonhuman
primat
studi
suggest
cell
requir
protect
rodent
zebov
specif
studi
use
liposomeencapsul
zebov
antigen
rao
colleagu
show
treatment
mice
antibodi
vaccin
abolish
protect
treatment
antibodi
effect
thu
indic
requir
lymphocyt
success
immun
similarli
deplet
cell
compromis
protect
mice
indic
cytotox
cell
requir
protect
conclus
result
show
vsvbase
zebov
vaccin
vsvdgzebovgp
caus
ill
immunocompromis
shivinfect
rhesu
macaqu
result
suffici
protect
efficaci
sever
compromis
anim
lethal
zebov
challeng
protect
immunocompromis
macaqu
appear
depend
cell
rather
develop
ebovspecif
antibodi
provid
strong
support
safeti
vsvbase
vector
develop
promis
vaccin
platform
use
human
data
encourag
number
shivinfect
macaqu
current
studi
small
addit
safeti
studi
need
order
determin
whether
vaccin
base
attenu
vsv
ultim
prove
safe
immunocompromis
human
